Zentalis Pharmaceuticals, Inc. (ZNTL) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Zentalis Pharmaceuticals reported revenue of $0, down 100.0% from $67.4M the year before. Net income was -$137.1M, or -$1.91 per diluted share. Operating activities generated -$125.2M of cash. At fiscal year end, Zentalis Pharmaceuticals held $289.0M in total assets against $72.8M in total liabilities, including $36.0M of cash and equivalents.
Open the full interactive Zentalis Pharmaceuticals financials → Quarterly statements, key ratios, valuation history and price charts.
Zentalis Pharmaceuticals Key Stats
| Share Price | $2.40 |
|---|---|
| Market Cap | $171.2M |
| Revenue YoY Growth | -100.0% |
| 52-Week Range | $1.28 – $6.61 |
| Shares Outstanding | 71.3 million (basic, 2026 Q2) |
Zentalis Pharmaceuticals Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $67.4M | $0 |
| Operating Income | -$118.8M | -$216.5M | -$227.3M | -$299.5M | -$191.2M | -$152.8M |
| Pre-Tax Income | -$118.1M | -$166.4M | -$237.6M | -$292.9M | -$165.7M | -$136.6M |
| Income Tax | $444,000 | -$297,000 | -$469,000 | -$601,000 | $177,000 | $442,000 |
| Net Income | -$117.8M | -$158.7M | -$236.8M | -$292.2M | -$165.8M | -$137.1M |
| Diluted EPS | -$4.19 | — | -$4.48 | -$4.47 | -$2.33 | -$1.91 |
Zentalis Pharmaceuticals Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$26.7M | -$35.2M | -$35.4M | -$42.3M |
| Diluted EPS | -$0.37 | -$0.49 | -$0.50 | -$0.59 |
Zentalis Pharmaceuticals Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $55.0M | $59.7M | $43.1M | $28.0M | $33.9M | $36.0M |
| Current Assets | $345.1M | $350.8M | $451.9M | $496.7M | $386.1M | $253.2M |
| Total Assets | $365.6M | $454.5M | $539.3M | $551.7M | $430.3M | $289.0M |
| Current Liabilities | $28.6M | $43.9M | $56.6M | $69.4M | $52.7M | $36.6M |
| Total Liabilities | $32.2M | $90.0M | $105.3M | $114.3M | $93.2M | $72.8M |
| Shareholders' Equity | $333.4M | $364.5M | $434.0M | $437.3M | $337.2M | $216.2M |
Zentalis Pharmaceuticals Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$86.8M | -$154.1M | -$163.8M | -$207.8M | -$170.9M | -$125.2M |
| Cash From Investing | -$284.8M | -$18.1M | -$114.2M | -$44.5M | $176.6M | $131.6M |
| Cash From Financing | $360.4M | $178.5M | $261.0M | $237.3M | $108,000 | -$4.3M |
| Free Cash Flow | -$87.6M | -$160.2M | -$166.3M | -$208.4M | -$171.1M | -$125.2M |
Figures from Zentalis Pharmaceuticals' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Zentalis Pharmaceuticals financials page for every line item.
Zentalis Pharmaceuticals Company Profile
| Ticker | ZNTL |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | San Diego, California |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001725160 |
Frequently Asked Questions
What was Zentalis Pharmaceuticals' revenue in fiscal 2025?
Zentalis Pharmaceuticals (ZNTL) reported revenue of $0 for fiscal 2025.
What is Zentalis Pharmaceuticals' annual revenue history?
Zentalis Pharmaceuticals' annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $0; 2024: $67.4M; 2025: $0.
What was Zentalis Pharmaceuticals' net income in fiscal 2025?
Zentalis Pharmaceuticals reported net income of -$137.1M for fiscal 2025.
What was Zentalis Pharmaceuticals' earnings per share (EPS) in fiscal 2025?
Zentalis Pharmaceuticals' diluted EPS was -$1.91 for fiscal 2025 (adjusted for any later stock splits).
What was Zentalis Pharmaceuticals' revenue last quarter?
In its most recent reported quarter (2026 Q2), Zentalis Pharmaceuticals reported revenue of $0.
How many shares of Zentalis Pharmaceuticals are outstanding?
Zentalis Pharmaceuticals reported a weighted average of 71.3 million basic shares outstanding in 2026 Q2.
What is Zentalis Pharmaceuticals' market cap?
Based on its latest closing price, Zentalis Pharmaceuticals (ZNTL) has a market capitalization of about $171.2M.
When does Zentalis Pharmaceuticals' fiscal year end?
Zentalis Pharmaceuticals' fiscal year end, as registered with the SEC, is December 31.
Where is Zentalis Pharmaceuticals headquartered?
Zentalis Pharmaceuticals lists its business address in San Diego, California in its SEC filings.